Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIT Trial
2017-003243-37Phase 3Suspended
- Sponsor
- MUST Coordinating Centre
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab, ozurdex, methotrexate in uveitic macular edema (UME), sponsored by MUST Coordinating Centre. Started Sep 2017; status: suspended.
02
Drugs
ranibizumabozurdexmethotrexate
03
Conditions
uveitic macular edema (UME)
Beyond the preview
Go deeper on 2017-003243-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003243-37.